Related Experiment Videos
How should we proceed with disease-modifying treatments for multiple sclerosis?
P B Andersson1, E Waubant, D E Goodkin
1University of California San Francisco/Mt Zion Multiple Sclerosis Center 94115, USA.
Lancet (London, England)
|March 1, 1997
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS.
AJNR. American journal of neuroradiology·2020
Multiple sclerosis onset after granulocyte macrophage colony-stimulating factor withdrawal.
Multiple sclerosis and related disorders·2018
Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
Journal of the neurological sciences·2017
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
European journal of neurology·2016
Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection.
European journal of neurology·2015
Advancing the relevance of clinical trials for older patients.
Lancet (London, England)·2026
Development of a Novel, Eco-Friendly Mechanical Cell Lysis Process Using Hollow Fiber Filter for AAV Manufacturing.
Biotechnology and bioengineering·2026
Programmed repair of disease-causing UGA premature termination codons in mammalian brain.
Nucleic acids research·2026
Case Report: Novel homozygous pathogenic variant of the SPG20 gene causes the Troyer syndrome in China.
Frontiers in genetics·2026
Molecular profiling and functional analyses of umbilical cord mesenchymal stem cell-derived extracellular vesicles for dry eye diseases.
Extracellular vesicles and circulating nucleic acids·2026
Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.
Frontiers in immunology·2026
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis After Failure of Ustekinumab: A Multicenter Retrospective Study.
The Journal of clinical and aesthetic dermatology·2026